Sensitivity of neuronal nicotinic acetylcholine receptors to the opiate antagonists naltrexone and naloxone: Receptor blockade and up-regulation

Bioorganic and Medicinal Chemistry Letters

Volumn 14, Issue 8, 2004, Pages 1879-1887

  Almeida, Luis E F ^a   Pereira, Edna F R ^a   Camara, Adriana L ^a,c   Maelicke, Alfred ^b   Albuquerque, Edson X ^a,c  

^a UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY MEDICAL CENTER MAINZ   (Germany)

^c FEDERAL UNIVERSITY OF RIO DE JANEIRO   (Brazil)

Author keywords

HEK cells; Naloxone; Naltrexone; Nicotine; Nicotinic receptors; Organotypic cultures; Smoking cessation

Indexed keywords

NALOXONE; NALTREXONE; NICOTINIC RECEPTOR; OPIATE ANTAGONIST;

ARTICLE; CONTROLLED STUDY; DRUG RECEPTOR BINDING; EMBRYO; EMBRYO CELL; FIBROBLAST; HIPPOCAMPUS; HUMAN; HUMAN CELL; KIDNEY CELL; PROTEIN EXPRESSION; RECEPTOR UPREGULATION; SMOKING CESSATION;

CELL LINE; GENE EXPRESSION; HUMANS; NALOXONE; NALTREXONE; NARCOTIC ANTAGONISTS; NEURONS; NICOTINE; PATCH-CLAMP TECHNIQUES; RECEPTORS, NICOTINIC; SENSITIVITY AND SPECIFICITY; SMOKING CESSATION; STRUCTURE-ACTIVITY RELATIONSHIP; TIME FACTORS; UP-REGULATION;

EID: 1642588152     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmcl.2004.01.004     Document Type: Article

References (49)

1. Volkow N.B., Fowler J.S., Wang G.-J., Goldstein R. Neurobiol. Learn. Mem. 78:2002;610.
2. Bhargava H.N. Gen. Pharmacol. 22:1991;767.
3. Dani J.A., DeBiasi M. Pharmacol. Biochem. Behav. 70:2001;439.
4. Picciotto M. Drug Alcohol Depend. 51:1998;165.
5. Berke J.D., Hyman S.E. Neuron. 25:2000;515.
6. Mello N.K., Mendelson J.H., Sellers M.L., Kuehnle J.C. Psychopharmacology (Berl.). 67:1980;45.
7. Aceto M.D., Scates S.M., Ji Z., Bownan E.R. Eur. J. Pharmacol. 248:1993;333.
8. Karras A., Kane J.M. Life Sci. 27:1980;1541.
9. Nemeth-Coslett R., Griffiths R.R. Psychopharmacology (Berl.). 89:1986;261.
10. Wewers M.E., Dhatt R., Tejwani G.A. Psychopharmacology (Berl.). 140:1998;185.
11. Wong G.Y., Wolter T.D., Croghan G.A., Croghan I.T., Offord K.P., Hurt R.D. Addiction. 94:1999;1227.
12. Sutherland G., Stapleton J.A., Russel M.A.H., Feyerabend C. Psychopharmacology (Berl.). 120:1995;418.
13. Hutchison K.E., Monti P.M., Rohsenow D.J., Swift R.M., Colby S.M., Cnys M., Niaura R.S., Sirota A.D. Psychopharmacology (Berl.). 142:1999;139.
14. Brauer L.H., Behm F.M., Westman E.C., Patel P., Rose J.E. Psychopharmacology (Berl.). 143:1999;399.
15. Madsen B.W., Albuquerque E.X. FEBS Lett. 182:1985;20.
16. Oliveira L., Madsen B.W., Kapai N., Sherby S.M., Swanson K.L., Eldefrawi M.E., Albuquerque E.X. Eur. J. Pharmacol. 140:1987;331.
17. Almeida L.E.F., Pereira E.F.R., Alkondon M., Fawcett W.P., Randall W.R., Albuquerque E.X. Neuropharmacology. 39:2000;2740.
18. Samochocki M., Hoffle A., Fehrenbacher A., Jostock R., Ludwig J., Christner C., Radina M., Zerlin M., Ullmer C., Pereira E.F.R., Lubbert H., Albuquerque E.X., Maelicke A. J. Pharmacol. Exp. Ther. 305:2003;1024.
19. Hamil O.P., Marty A., Neher E., Sakmann B., Sigworth F.J. Pflügers. Arch. 39:1981;85.
20. Montes J.G., Alkondon M., Pereira E.F.R., Castro N.G., Albuquerque E.X. Methods Neurosci. 19:1994;121.
21. Covernton P.J.O., Connolly J.G.J. Neurosci. Methods. 96:2000;63.
22. Almeida, L. E. F.; Pereira, E. F. R.; Maelicke, A.; Albuquerque, E. X. Expression of two nicotinic receptor isoforms in HEK 293 cells stably transfected with α4 and β2 subunits. 31st Annual Meeting of The Society for Neuroscience, San Diego, CA, 10-15 Nov 2001; Society for Neuroscience: Washington, DC, 2001.
23. Buisson B., Bertrand D. J. Neurosci. 21:2001;1819.
24. Nelson M.E., Kuryatov A., Choi C.H., Zhou Y., Lindstrom J. Mol. Pharmacol. 63:2003;332.
25. Zwart R., Vijverberg H. Mol. Pharmacol. 54:1998;1124.
26. Papke R.L., Boulter J., Patrick J., Heinemann S. Neuron. 3:1989;589.
27. Buisson B., Gopalakrishnan M., Arneric S.P., Sullivan J.P., Bertrand D.J. J. Neurosci. 16:1996;7880.
28. Albuquerque E.X., Desphande S.S., Aracava Y., Alkonodon M., Daly J.W. FEBS Letters. 199:1986;113.
29. Sabey K., Paradiso K., Zahang J., Steinbach J.H. Mol. Pharmacol. 55:1999;58.
30. Costa A.C.S., Albuquerque E.X. J. Pharmacol. Exp. Ther. 286:1994;503.
31. Dani J.A., Heinemann S. Neuron. 16:1996;905.
32. Covey L.S., Glassman A.H., Stetner F. J. Addict. Dis. 18:1999;31.
33. King A.C., Meyer P.J. Pharmacol. Biochem. Behav. 66:2000;563.
34. Ahmadi J., Ashkani H., Ahmadi M., Ahmadi N. J. Subst. Abuse Treat. 24:2003;251.
35. Verebey K., Volavka J., Mule S.J., Resnick R.B. Clin. Pharmacol. Ther. 20:1976;315.
36. Taylor S.M., Rodders R.N., Lynn R.K., Gerber N. J. Pharmacol. Exp. Ther. 213:1980;289.
37. Volavka J., Resnick R.B., Kestenbaum R.S., Freedman A.M. Biological Psychiatry. 11:1976;679.
38. Meyer M.C., Straughn A.B., Lo M.-W., Schary W., Whitney C.C. J. Clin. Psychiatry. 45:1984;15. 2.
39. Braude, C. M.; Morrison, J. M. In Narcotic Antagonists: Naltrexone Progress Report; Julius, D., Renault, P., Eds.; National Institute on Drug Abuse Research Monograph 9, 1976, p 16.
40. Stolerman I.P., Goldfarb T., Fink R., Jarvik M.E. Psychopharmacology (Berl.). 28:1973;247.
41. Stoppini L., Buchs P.-A., Muller D. J. Neurosci. Methods. 37:1991;173.
42. st Annual Meeting of The Society for Neuroscience, San Diego, CA, 10-15 Nov 2001; Society for Neuroscience: Washington, DC, 2001.
43. Blanton M.G., Lo Turco J.J., Kriegstein A.R. J. Neurosci. Methods. 30:1989;203.
44. Svoboda K.R., Adams C.E., Lupica C.R. J. Neurosci. 19:1999;85.
45. Almeida, L. E. F.; Pereira, E. F. R.; Albuquerque, E. X. Prolonged exposure to nanomolar concentrations of nicotine synchronizes gabaergic synaptic activity. 32nd Annual Meeting of The Society for Neuroscience, Orlando, Fl, 2-7 Nov 2002; Society for Neuroscience: Washington, DC, 2002.
46. Ferrer-Montiel A.V., Montal M.S., Diaz-Munoz M., Montal M. Proc. Natl. Acad. Sci. U.S.A. 88:1991;10213.
47. Margiotta J.F., Berg D.K., Dionne V.E. Proc. Natl. Acad. Sci. U.S.A. 84:1987;8155.
48. Liu Q.S., Berg D.K. J. Neurosci. 19:1999;10280.
49. Khiroug L., Sokolova E., Giniatullin R., Afzalov R., Nistri A. J. Neurosci. 18:1998;2458.